Yrondi A

Department of Psychiatry Toulouse University Hospital, Treatment Resistant Depression and Bipolar Expert Center, FondaMental.

6 papers · ORCID

ArticleKetamine

Safety of Intranasal Esketamine Administration in Brugada Syndrome: Two Clinical Case Reports.

Bobet A, Yrondi A, Rollin A +3

Europe PMC2026
ArticlePsychedelics

Older Adults in Psychedelic-Assisted Therapy Trials: A Systematic Review

Bouchet L, Sager Z, Yrondi A +5

Europe PMC2024
ArticleKetamine

French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN) guidelines for the management of patients with partially responsive depression and treatment-resistant depression: Update 2024.

Yrondi A, Javelot H, Nobile B +7

Europe PMC2025
ArticlePsilocybin

Older adults in psychedelic-assisted therapy trials: A systematic review.

Bouchet L, Sager Z, Yrondi A +5

Europe PMC2024
ArticleKetamine

[Funding of psychiatry in France, the problem of expensive drugs. Example of Esketamine in the case of resistant depressive episodes].

Taillefer de Laportalière T, Jullien A, Eyvrard F +5

Europe PMC2024
ArticleKetamine

Reporting of harms in clinical trials of esketamine in depression: a systematic review.

Taillefer de Laportalière T, Jullien A, Yrondi A +2

Europe PMC2023